Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia
International Journal of Angiology · 01.12.2024 · 33 (04) · 318-321
DOI: 10.1055/s-0041-1726366 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Angiology, erschienen am 01.12.2024. Verfasst von Luis F Morales und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, North Shore University Hospital, Manhasset, New York. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
We describe the clinical course of a 65-year-old male patient who suffered from hydrocarbon-induced myelodysplasia and was successfully treated with the thrombopoietin receptor agonist (TPO-RA), romiplostim. Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis, cytopenias, and increased risk of leukemic transformation. Here, we present a clinical vignette of MDS-associated thrombocytopenia refractory to first-line drugs as well as the TPO-RA, eltrombopag. To date, romiplostim is an U.S. Food and Drug Administration (FDA)-approved drug for idiopathic thrombocytopenic purpura and thrombocytopenia secondary to liver disease. Of note, currently the FDA advises against its use in MDS based on previous long-term safety concerns. Since the therapeutic options for thrombocytopenia in MDS patients are sparse, repurposing and reassessing romiplostim in this setting have been the focus of recent studies. At the time of writing, no published double-blind randomized clinical trials have conducted a head-to-head comparison between romiplostim and eltrombopag in thrombocytopenic MDS patients. To the best of our knowledge, for a thrombocytopenic patient in the setting of MDS, this is the first documented report of refractory clinical response after a 2-year use of eltrombopag in which replacement of treatment with romiplostim resulted in sustained physiological counts of thrombocytes within four weeks.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, North Shore University Hospital, Manhasset, New York.
- Elmezzi Graduate School of Molecular Medicine, Manhasset, New York.
- Feinstein Institutes for Medical Research, Manhasset, New York.
- Department of Emergency Medicine, North Shore University Hospital, Manhasset, New York.
- Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.
- Jacobs School of Medicine and Biomedical Sciences, Buffalo, University at Buffalo, Buffalo, New York.
ORCID-Profile: Santiago J Miyara
Zitieren
APA
Morales, L. F., Miyara, S. J., Guevara, S., Metz, C. N., Shoaib, M., Watt, S., Zafeiropoulos, S., McCann-Molmenti, A., Hayashida, K., Takegawa, R., Shinozaki, K., Choudhary, R. C., Brindley, E. C., Nishikimi, M., Kressel, A. M., Alsalmay, Y. M., Mazzotta, E. A., Cho, Y. M., Aranalde, G. I., …, & Molmenti, E. P. (2024). Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia. International Journal of Angiology, 33(04), 318-321. https://doi.org/10.1055/s-0041-1726366
Vancouver
Morales LF, Miyara SJ, Guevara S, Metz CN, Shoaib M, Watt S, et al. Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia. International Journal of Angiology. 2024;33(04):318-321. doi:10.1055/s-0041-1726366
BibTeX
@article{Morales2024,
author = {Morales, Luis F and Miyara, Santiago J and Guevara, Sara and Metz, Christine N and Shoaib, Muhammad and Watt, Stacey and Zafeiropoulos, Stefanos and McCann-Molmenti, Alexia and Hayashida, Kei and Takegawa, Ryosuke and Shinozaki, Koichiro and Choudhary, Rishabh C and Brindley, Elena C and Nishikimi, Mitsuaki and Kressel, Adam M and Alsalmay, Yaser M and Mazzotta, Elvio A and Cho, Young Min and Aranalde, Gabriel I and Grande, Daniel A and Zanos, Stavros and Shore-Lesserson, Linda and Becker, Lance B and Molmenti, Ernesto P},
title = {Sequential Use of Romiplostim after Eltrombopag for Refractory Thrombocytopenia in Hydrocarbon-Induced Myelodysplasia},
journal = {International Journal of Angiology},
year = {2024},
volume = {33},
number = {04},
pages = {318--321},
doi = {10.1055/s-0041-1726366}
}
EUVIMED